Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction

Leuk Lymphoma. 2005 Nov;46(11):1667-70. doi: 10.1080/10428190500220514.

Abstract

We report a 50-year-old patient with idiopathic hypereosinophilic syndrome with trisomy 8 who experienced a complete and durable hematological and cytogenetic remission with low-dose imatinib therapy. He also had a significant reversal of cardiac dysfunction with a reduction in cardiac hypertrophy, resolution of pericardial effusion and mitral and tricuspid regurgitation. He remained in remission 3 years after therapy.

Publication types

  • Case Reports

MeSH terms

  • Aortic Valve Insufficiency
  • Benzamides
  • Cardiomegaly
  • Chromosomes, Human, Pair 8*
  • Cytogenetic Analysis
  • Heart Diseases*
  • Humans
  • Hypereosinophilic Syndrome / complications*
  • Hypereosinophilic Syndrome / drug therapy*
  • Hypereosinophilic Syndrome / genetics
  • Imatinib Mesylate
  • Middle Aged
  • Mitral Valve Insufficiency
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Remission Induction / methods
  • Trisomy*

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate